Your browser doesn't support javascript.
loading
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition
Kevin J Kramer; Nicole V Johnson; Andrea R Shiakolas; Naveenchandra Suryadevara; Sivakumar Periasamy; Nagarajan Raju; Jazmean K Williams; Daniel Wrapp; Seth J Zost; Clinton M Holt; Ching-Lin Hsieh; Rachel E Sutton; Ariana Paulo; Edgar Davidson; Benjamin J Doranz; James E. Crowe; Alexander Bukreyev; Robert H Carnahan Jr.; Jason S McLellan; Ivelin S Georgiev.
Afiliación
  • Kevin J Kramer; Vanderbilt University
  • Nicole V Johnson; The University of Texas at Austin
  • Andrea R Shiakolas; Vanderbilt University
  • Naveenchandra Suryadevara; Vanderbilt University Vaccine Center
  • Sivakumar Periasamy; University of Texas Medical Branch at Galveston
  • Nagarajan Raju; Vanderbilt University Vaccine Center
  • Jazmean K Williams; Integral Molecular
  • Daniel Wrapp; University of Texas at Austin
  • Seth J Zost; Vanderbilt University Vaccine Center
  • Clinton M Holt; Vanderbilt University
  • Ching-Lin Hsieh; University of Texas at Austin
  • Rachel E Sutton; Vanderbilt University Vaccine Center
  • Ariana Paulo; Vanderbilt Vaccine Center
  • Edgar Davidson; Integral Molecular
  • Benjamin J Doranz; Integral Molecular
  • James E. Crowe; Vanderbilt University Medical Center
  • Alexander Bukreyev; University of Texas Medical Branch at Galveston
  • Robert H Carnahan Jr.; Vanderbilt University Medical Center
  • Jason S McLellan; The University of Texas at Austin
  • Ivelin S Georgiev; Vanderbilt University Medical Center
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-444004
ABSTRACT
The emergence of novel SARS-CoV-2 lineages that are more transmissible and resistant to currently approved antibody therapies poses a considerable challenge to the clinical treatment of COVID-19. Therefore, the need for ongoing discovery efforts to identify broadly reactive monoclonal antibodies to SARS-CoV-2 is of utmost importance. Here, we report a panel of SARS-CoV-2 antibodies isolated using the LIBRA-seq technology from an individual who recovered from COVID-19. Of these antibodies, 54042-4 showed potent neutralization against authentic SARS-CoV-2 viruses, including variants of concern (VOCs). A cryo-EM structure of 54042-4 in complex with the SARS-CoV-2 spike revealed an epitope composed of residues that are highly conserved in currently circulating SARS-CoV-2 lineages. Further, 54042-4 possesses unique genetic and structural characteristics that distinguish it from other potently neutralizing SARS-CoV-2 antibodies. Together, these findings motivate 54042-4 as a lead candidate for clinical development to counteract current and future SARS-CoV-2 VOCs.
Licencia
cc_no
Texto completo: 1 Colección: 09-preprints Banco de datos: PREPRINT-BIORXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Banco de datos: PREPRINT-BIORXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint